Editorial

From the desk of the editor

Welcome to the May 2012 homepage edition of i2P-Information to Pharmacists. Rollo Manning has been having some time out having staples removed from the site of his open heart surgery.He is now at home recuperating in Darwin, having arrived home last Friday, beating a cold and hasty retreat from Canberra.We all wish him a speedy recovery and hopefully, he will be fit enough to contribute by next month.
This month, Pharmedia discusses the toll that is taken when someone complains about you to an authority without good cause. Well, the good news is that you can now take action to protect yourself if such a complaint is made, and that may even include action for defamation. Read about a recent case involving two doctors, with Mark Coleman drawing on personal experience to illustrate.

read more
open full screen

Columns

Recent Comments

Click here to read...

Past Editions

Volume 1 Number 1
Volume 1 Number 2
Volume 1 Number 3
Volume 1 Number 4
Volume 1 Number 5
Volume 1 Number 6
Volume 1 Number 7
Volume 2 Number 1
Volume 2 Number 2
Volume 2 Number 3
Volume 2 Number 4
Volume 2 Number 5
Volume 2 Number 6
Volume 2 Number 7
Volume 2 Number 8
Volume 2 Number 9
Volume 2 Number 10
Volume 2 Number 11
Volume 3 Number 1
Volume 3 Number 2
Volume 3 Number 3
Volume 3 Number 4
Volume 3 Number 5
Volume 3 Number 6
Volume 3 Number 7
Volume 3 Number 8
Volume 3 Number 9
Volume 3 Number 10
Volume 3 Number 11
Volume 4 Number 1
Volume 4 Number 2
Volume 4 Number 3
Volume 4 Number 4
Volume 4 Number 5
Volume 4 Number 6
Volume 4 Number 7
Volume 4 Number 8
Volume 4 Number 9
Volume 4 Number 10
Volume 4 Number 11
Volume 5 Number 1
Volume 5 Number 2
Volume 5 Number 3
Volume 5 Number 4

i2P Archives

Climate Change

EPublications

Click here for a list of epublications

New drug shrinks brain tumours in melanoma patients

• Printer-friendly version
• Send to friend
• PDF version
• Share

	Staff Researcher articles by this author...
Editing and Researching news and stories about Australian and International Pharmacy Issues

Australian researchers have reported promising results with a new drug that shrinks brain tumours in melanoma patients. Their findings are published in The Lancet medical journal today.
Medical researchers at the University of Sydney, Melanoma Institute Australia, Sydney's Westmead Hospital and Westmead Millennium Institute, say a new drug they have been testing to treat deadly melanoma in the body also shows, for the first time, an ability to shrink secondary tumours (metastases) in the brains of patients with advanced forms of the disease.

open this article full screen

They say the new drug may add months to the lives of patients whose melanoma has spread to the brain. Most patients with brain metastases die within four months. The trial's results, however, showed brain tumours in nine of the 10 patients shrank within the first six weeks. All 10 patients survived beyond five months, two patients survived beyond 12 months. One patient was alive at 19 months.

The drug called Dabrafenib works by targeting a gene mutation found in melanoma cancer, called the BRAF mutation, which is present in 50 percent of human melanomas. The drug works by binding to the activated mutant form of the BRAF protein in the melanoma cell, causing the cell to stop proliferating. In many cases it shrinks and disappears.

The lead author of the study, Dr Georgina Long, from the University of Sydney, Melanoma Institute Australia and Westmead Hospital said, "This is the first evidence that we have a systemic drug therapy that helps prolong survival in patients with multiple melanoma brain metastases. The findings are among the most important in the history of drug treatment for melanoma.

"Currently there is no effective systemic treatment for melanoma brain metastases, and patients whose cancer has spread to the brain are frequently excluded from promising clinical trials. Until now, there has not been a single drug that has shrunk brain metastases in more than 10 out of 100 patients with metastatic melanoma. This drug had a 90 percent success rate in reducing the size of brain metastases.

"Brain metastases in melanoma are a major unsolved problem. Up to this point, melanoma has been notoriously resistant to drug therapy in general, and responses in highly lethal brain metastases are particularly uncommon. Providing these early data are supported in larger cohorts of patients and durable responses are confirmed, this activity in the brain may assist in addressing a large unmet need in patients with metastatic melanoma worldwide," Dr Long said.

Clinical Newsfeed

Click here to read more...

Research Reports

Practice Development

Information Technology

Preventive Medicine

i2P Alliance Partners